Journal article · 2023 · Open access

Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations

Gabriel Vinderola, Céline Druart, Luis Gosálbez, Seppo Salminen, Nina Vinot, Sarah Lebeer

Frontiers in Pharmacology, 14, 1239745 · Published 8 September 2023 · DOI 10.3389/fphar.2023.1239745

Free PDFView at the publisherCite this paper

In brief

“Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations” is a 2023 journal article by Gabriel Vinderola and 5 co-authors, published in Frontiers in Pharmacology. OpenAlex counts 55 citations as of 15 November 2026, which puts it in the top 3% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Pharmacology.

Citations
55
Most cited in
2026 (28)
Field-weighted impact
6.20
References
30
Authors
6

Abstract

Diverse terms have been used in the literature to refer to the health benefits obtained from the administration of non-viable microorganisms or their cell fragments and metabolites. In an effort to provide continuity to this emerging field, the International Scientific Association of Probiotics and Prebiotics (ISAPP) convened a panel of experts to consider this category of substances and adopted the term postbiotic, which they defined as a "preparation of inanimate microorganisms and/or their components that confers a health benefit on the host." This definition does not stipulate any specific health benefit, finished product, target population or regulatory status. In this perspective article, we focused on postbiotics developed for pharmaceutical uses, including medicinal products and medical devices. We address how this field is regulated for products based on inanimate microorganisms, marketing considerations and existing examples of postbiotics products developed as cosmetics for the skin, for vaginal health, and as orally consumed products. We focus on the European Union for regulatory aspects, but also give examples from other geographical areas.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Vinderola, G., Druart, C., Gosálbez, L., Salminen, S., Vinot, N., & Lebeer, S. (2023). Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations. Frontiers in Pharmacology, 14, 1239745. https://doi.org/10.3389/fphar.2023.1239745

MLA 9

Vinderola, Gabriel, et al. “Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations.” Frontiers in Pharmacology, vol. 14, 2023, p. 1239745. https://doi.org/10.3389/fphar.2023.1239745.

Chicago

Vinderola, Gabriel, Céline Druart, Luis Gosálbez, Seppo Salminen, Nina Vinot, and Sarah Lebeer. 2023. “Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations.” Frontiers in Pharmacology 14: 1239745. https://doi.org/10.3389/fphar.2023.1239745.

Harvard

Vinderola, G. et al. (2023) ‘Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations’, Frontiers in Pharmacology, 14, p. 1239745. doi:10.3389/fphar.2023.1239745.

IEEE

G. Vinderola, C. Druart, L. Gosálbez, S. Salminen, N. Vinot, and S. Lebeer, “Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations,” Frontiers in Pharmacology, vol. 14, p. 1239745, 2023, doi: 10.3389/fphar.2023.1239745.

BibTeX

@article{vinderola2023postbiotics,
  title     = {{Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations}},
  author    = {Vinderola, Gabriel and Druart, Céline and Gosálbez, Luis and Salminen, Seppo and Vinot, Nina and Lebeer, Sarah},
  journal   = {Frontiers in Pharmacology},
  year      = {2023},
  volume    = {14},
  pages     = {1239745},
  doi       = {10.3389/fphar.2023.1239745},
  url       = {https://doi.org/10.3389/fphar.2023.1239745}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202455
20252222
20262828

Its field-weighted citation impact is 6.20: it has been cited 6.20 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods

  • postbiotics
  • medical devices
  • regulatory considerations
  • product marketing
  • probiotics
  • prebiotics
  • cosmetics
  • vaginal health

Work with this paper

Most-cited papers in Agricultural and Biological Sciences

All highly cited Agricultural and Biological Sciences papers

Questions about this paper

How do I cite this paper in APA style?

Vinderola, G., Druart, C., Gosálbez, L., Salminen, S., Vinot, N., & Lebeer, S. (2023). Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations. Frontiers in Pharmacology, 14, 1239745. https://doi.org/10.3389/fphar.2023.1239745

How many times has this paper been cited?

55 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Frontiers in Pharmacology.

Who wrote this paper?

Gabriel Vinderola, Céline Druart, Luis Gosálbez, Seppo Salminen, Nina Vinot, Sarah Lebeer.

What is the DOI of this paper?

10.3389/fphar.2023.1239745. The permanent link is https://doi.org/10.3389/fphar.2023.1239745.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.